- Trials with a EudraCT protocol (143)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
143 result(s) found for: Refractory anemia.
Displaying page 1 of 8.
EudraCT Number: 2005-004737-17 | Sponsor Protocol Number: DARB-MDS | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA BIANCHI-MELACRINO-MORELLI | |||||||||||||
Full Title: Evaluation of the Efficacy of Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelodysplastic Syndrome | |||||||||||||
Medical condition: Anemia in patients with myelodysplastic syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001257-22 | Sponsor Protocol Number: 20210112 | Start Date*: 2023-03-29 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Amgen, Inc. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Non Asian Adult Severe Aplastic Anemia (SAA) Subjects who are Either Previously Untreated With Immunosuppressive T... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Aplastic anemia (AA) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011613-24 | Sponsor Protocol Number: HOVON102AML/SAKK30/09 | Start Date*: 2010-01-25 | ||||||||||||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||||||||||||
Full Title: Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously ... | ||||||||||||||||||||||||||||
Medical condition: - a cytopathologically confirmed diagnosis of AML according WHO classification (excluding acute promyelocytic leukaemia) or - a diagnosis of refractory anemia with excess of blasts (RAEB) and ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) BE (Completed) SE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000348-22 | Sponsor Protocol Number: KER047-IR-201 | Start Date*: 2021-08-10 |
Sponsor Name:Keros Therapeutics, Inc. | ||
Full Title: A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA | ||
Medical condition: Iron-Refractory Iron-Deficiency Anemia (IRIDA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005322-22 | Sponsor Protocol Number: RV-MDS-PI-0550-REV/AZA | Start Date*: 2012-06-11 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | ||||||||||||||||||
Full Title: A Phase II Study exploring the feasibility of Azacitidine and Lenalidomide use (combination vs sequential treatment) for Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2) | ||||||||||||||||||
Medical condition: Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005370-62 | Sponsor Protocol Number: ANAKIN-RA-DIABETES | Start Date*: 2013-02-18 | ||||||||||||||||
Sponsor Name:OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA | ||||||||||||||||||
Full Title: “No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabe... | ||||||||||||||||||
Medical condition: rheumatoid arthritis and type 2 diabetes mellitus as comorbidity. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005264-14 | Sponsor Protocol Number: P130103 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: NA | |||||||||||||
Medical condition: Fanconi Anemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006329-42 | Sponsor Protocol Number: CAD0111 | Start Date*: 2012-10-11 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
Full Title: Short course of Bortezomib in anemic patients with refractory cold agglutinin disease | |||||||||||||
Medical condition: Anaemia with refractory cold agglutinin disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002502-31 | Sponsor Protocol Number: RP-L102-0118 | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemi... | |||||||||||||
Medical condition: Fanconi anemia (subtype A) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003166-91 | Sponsor Protocol Number: CETB115E2201 | Start Date*: 2019-05-22 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, rela... | |||||||||||||
Medical condition: Refractory, relapsed or treatment naïve severe aplastic anemia (SAA) or recurrent aplastic anemia (AA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001223-31 | Sponsor Protocol Number: KAISII | Start Date*: 2016-10-11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:King's College Hospital NHS Foundation Trust | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003675-18 | Sponsor Protocol Number: ANX005-wAIHA-02 | Start Date*: 2021-01-11 | |||||||||||
Sponsor Name:Annexon, Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolyti... | |||||||||||||
Medical condition: Warm Autoimmune Hemolytic Anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) FR (Completed) CZ (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006197-88 | Sponsor Protocol Number: FANCOSTEM-1 | Start Date*: 2012-03-22 | |||||||||||
Sponsor Name:Cristina Díaz de Heredia Rubio | |||||||||||||
Full Title: Clinical Phase II Trial to evaluate efficacy and safety of CD34+ cells mobilization and collection after treatment with plerixafor and filgrastim in patients with Fanconi anemia for subsequent tra... | |||||||||||||
Medical condition: Fanconi anemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000404-92 | Sponsor Protocol Number: HOVON 92 AML | Start Date*: 2008-09-12 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia... | ||||||||||||||||||
Medical condition: AML according to WHO classification (excluding acute promyelocytic leukaemia) or refractory anemia with excess of blasts (RAEB) and IPSS score ≥1.5 or therapy-related AML/RAEB or biphenotypic le... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-006100-12 | Sponsor Protocol Number: FANCOLEN-1 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS | |||||||||||||
Full Title: Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) for patients with... | |||||||||||||
Medical condition: Fanconi anemia (Subtype A) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016966-97 | Sponsor Protocol Number: CAD01 | Start Date*: 2010-06-08 | |||||||||||
Sponsor Name:Universitätsklinikum Essen | |||||||||||||
Full Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease ... | |||||||||||||
Medical condition: Cold agglutinin disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002652-33 | Sponsor Protocol Number: T-Haplo-for-SCD | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University Hospital of Regensburg | |||||||||||||
Full Title: A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014455-68 | Sponsor Protocol Number: HOVON103AMLTosedostat | Start Date*: 2010-08-16 | |||||||||||||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||||||||||||
Full Title: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and ... | |||||||||||||||||||||||
Medical condition: patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 1... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) BE (Completed) NO (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013094-17 | Sponsor Protocol Number: HOVON103AMLLEN | Start Date*: 2010-04-13 | |||||||||||||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||||||||||||
Full Title: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years an... | |||||||||||||||||||||||
Medical condition: patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 1... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) BE (Completed) NO (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003227-15 | Sponsor Protocol Number: KER050-MF-301 | Start Date*: 2022-02-08 | ||||||||||||||||||||||||||
Sponsor Name:Keros Therapeutics, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis | ||||||||||||||||||||||||||||
Medical condition: Myelfibrosis (MF) MF- associated cytopenias | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
